Search

Author/Creator Azim, H A

1. 1692PPhysicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. (23rd October 2018)

Authors:
Lambertini, M; Di Maio, M; Poggio, F; Pagani, O; Curigliano, G; Del Mastro, L; Paluch-Shimon, S; Loibl, S; Partridge, A H; Azim, H A; Peccatori, F A; Demeestere, I
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (23rd October 2018)

Authors:
Hui, R; Pearson, A; Cortes Castan, J; Campbell, C; Poirot, C; Azim, H A; Fumagalli, D; Lambertini, M; Daly, F; Arahmani, A; Perez-Garcia, J; Aftimos, P G; Bedard, P; Xuereb, L; Loibl, S; Loi, S; Pierrat, M-J; Turner, N C; André, F; Curigliano, G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 293PD_PRRibociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Zamagni, C; Campone, M; Kudryavcev, I; Brown-Glaberman, U; Cottu, P H; Ring, A; Lu, J; Martín, M; De Laurentiis, M; Zhou, K; Wu, J; Menon, L; Azim, H A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Abdel-Razeq, H; Cottu, P H; Ring, A; De Laurentiis, M; Lu, J; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Menon, L; Martín, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 333PRibociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Cardoso, F; Papazisis, K; De Laurentiis, M; Ring, A; Lu, J; Martín, M; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Zarate, J P; Cottu, P H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search